- Home
- KOSS vs NRXP Comparison
KOSS vs NRXP Comparison
Compare KOSS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOSS | NRXP |
|---|---|---|
| Founded | 1953 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.6M | 73.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | KOSS | NRXP |
|---|---|---|
| Price | $4.89 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 24.3K | ★ 446.3K |
| Earning Date | 10-30-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,493,080.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.58 | N/A |
| 52 Week Low | $4.00 | $1.15 |
| 52 Week High | $8.59 | $6.01 |
Technical Indicators
Market Signals| Indicator | KOSS | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 45.23 |
| Support Level | $4.80 | $2.22 |
| Resistance Level | $4.99 | $2.51 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 57.14 | 68.52 |
Price Performance
Historical ComparisonAbout KOSS Koss Corporation
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.